Feb. 20, 2019—Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. Oncologists haven’t had the right tools to predict drug interactions, other than in costly clinical trials. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy. The...
Jan. 21, 2019—A team of Vanderbilt University bioengineers announced a major breakthrough: designing a nanoscale particle that flips on cells' defenses to fight cancer.
Sep. 7, 2018—Turner Cockrell, a tight end on the Vanderbilt football team, was diagnosed with melanoma last November and will undergo a procedure Friday in hopes of staving off more cancerous cells. Throughout his battle, Cockrell has remained a Commodore—and his Vanderbilt family has stood by him.
Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.
Mar. 9, 2017—With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy.
Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
Mar. 12, 2015—Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.
Jan. 8, 2015—Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.